VRTX vs REGN — Key Metrics
| Metric | VRTX (VERTEX PHARMACEUTICALS INC) | REGN (REGENERON PHARMACEUTICALS INC) |
|---|---|---|
| Price | 536.45 | 945.53 |
| Market Cap | 136.01 Billion | 97.81 Billion |
| P/E (TTM) | 34.23 | 20.11 |
| P/B (Quarterly) | 6.436 | 2.865 |
| P/S (TTM) | 10.5 | 5.79 |
| Net Profit Margin (TTM) | 30.7 | 28.5 |
| Gross Margin (TTM) | 85.5 | 85.8 |
| ROE (TTM) | 20.1 | 15.1 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Outperform
Outperform
Recommendation Summary
Both stocks are projected to outperform the market over the next year. If you have to make a choice, Upfront Recommendation: REGN.
Financial Metrics
| VRTX | Metrics | REGN |
|---|---|---|
| $536.45 | Price | $945.53 |
| — | Market Capitalization | — |
| 34.23 | Price to Earnings Ratio | 20.11 |
| 10.5 | Price to Sales | 5.79 |
| 42.47 | Price to FCF Ratio | 25.56 |
| 12.28 | Price to Gross Profit | 6.75 |
| 32.0 | Price to R&D | 14.83 |
| 11.64 | Price to Current Assets | 4.7 |
VRTX vs REGN at a glance
Vertex Pharmaceuticals INC (VRTX) and Regeneron Pharmaceuticals INC (REGN) are both Biotechnology companies in the Healthcare sector. VRTX is the larger, at $136.0 billion in market value against $97.8 billion for REGN, about 1.4 times the size.
On trailing-twelve-month figures, VRTX trades at 34.2 times trailing earnings and REGN at 20.1; net profit margins are 30.7% and 28.5%.
The Upfront Investment model currently rates both Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.